6505--Aprepitant Capsules
ID: 36E79725R0029Type: Presolicitation
AwardedJun 10, 2025
$12.9M$12,857,811
AwardeeGOLDEN STATE MEDICAL SUPPLY, INC. CAMARILLO 93012
Award #:36E79725D0038
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/bb79ef087e924ebd84fff64b640fafdb/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting proposals for the supply of Aprepitant capsules, a pharmaceutical product essential for various government health facilities, including those under the Department of Defense and Indian Health Service. Offerors are required to provide pricing for multiple line items covering a base year and four option years, adhering to specific conditions such as a 0.5% Cost Recovery Fee and compliance with the Drug Supply Chain Security Act (DSCSA). The contract emphasizes the importance of maintaining current Good Manufacturing Practices (cGMP) and ensuring proper labeling and packaging of the products. Interested contractors should contact Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov for further details and must submit their proposals in accordance with the outlined requirements.

    Point(s) of Contact
    Matthew PoulinContract Specialist
    (708) 786-5186
    matthew.poulin@va.gov
    Files
    Title
    Posted
    36E79725R0029_1.docx
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0029 concerning the procurement of Aprepitant Capsules. This unrestricted procurement will cater to various federal entities, including the Department of Defense and the Bureau of Prisons, with the goal of ensuring a continuous supply of the medication. The contract will have a duration of one year plus four optional annual extensions. Offerors must provide a unique National Drug Code (NDC) number and ensure their label is the sole representation on the product. The solicitation is set to be released around March 25, 2025, with a closing date of April 8, 2025. It emphasizes the necessity for interested parties to stay updated via the SAM.gov website, as no paper copies will be provided. The estimated annual requirements indicate substantial quantities of Aprepitant in various dosages, highlighting the importance of this procurement in serving veterans and other federal health care facilities. Matthew Poulin serves as the point of contact for inquiries regarding this solicitation, reinforcing communication between the VA and potential offerors for clarification and submission processes.
    36E79725R0029.docx
    The document is a Request for Proposal (RFP) from the Department of Veterans Affairs for supplying various pharmaceutical products, specifically Aprepitant capsules, under a contract aimed at ensuring availability and committed-use pricing for government participants, including Veterans Affairs, Department of Defense, and Indian Health Service facilities. Offerors must provide prices for multiple line items covering the base year and four option years, with conditions set for pricing, including a 0.5% Cost Recovery Fee. To be eligible, contractors must submit necessary documentation including National Drug Codes (NDCs) and letters of commitment from manufacturers if they are not the manufacturers themselves. The contract's focus includes compliance with pharmaceutical standards and regulations, including adherence to Drug Supply Chain Security Act (DSCSA) requirements. Contractors are required to maintain cGMP (current Good Manufacturing Practices), and products must have appropriate labeling and packaging. The document outlines the evaluation, agreement terms, pricing mechanisms, and compliance assessments necessary for successful proposals, emphasizing the necessity of timely and accurate submissions and the importance of operational agreements with Prime Vendors for distribution.
    Similar Opportunities
    Pharmaceutical Repackaging Services for National CMOP (770)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for pharmaceutical repackaging services for the National Consolidated Mail Outpatient Pharmacy (CMOP) program. The contract, identified as 36C77026R0004, is a firm-fixed-price, indefinite-delivery agreement intended to support the repackaging of government-purchased oral solid pharmaceuticals into various bottle sizes for distribution to over 7 million veterans. The contract spans a five-year ordering period from February 1, 2026, to January 31, 2031, with a potential six-month extension, and has a minimum value of $20 million and a maximum value of $125 million. Interested contractors should contact Renee Kreutzer at renee.kreutzer@va.gov for further details and must submit their proposals by the specified deadlines, ensuring compliance with all relevant regulations and standards.
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking information from domestic pharmaceutical manufacturers through a Request for Information (RFI) designated 36C77026Q0061, aimed at supporting the Consolidated Mail Outpatient Pharmacy (CMOP) in fulfilling its Open Market (OM) purchasing needs. The RFI seeks to identify both small and large businesses capable of providing a range of pharmaceutical products and ancillary items, with a focus on those manufactured in the United States, to enhance the supply chain for approximately 450,000 prescriptions mailed daily to Veterans. Interested manufacturers are required to submit detailed company and product information, including FDA-approved NDC numbers and operational capabilities, by March 15, 2026, at 4:30 PM CT. For further inquiries, respondents can contact Michael McAlhaney at Michael.McAlhaney@va.gov or (913) 684-1976.
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    VA Direct to Patient supply services
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking small business vendors to provide direct delivery supply services for medical and surgical items to Veteran patients through its Consolidated Mail Outpatient Pharmacy (CMOP) program. The contractor must demonstrate at least two years of experience, the capacity to process approximately 14 million prescriptions annually, and the ability to maintain compliance with federal and state regulations while ensuring a 48-hour average turnaround time for prescription fulfillment. This opportunity is critical for ensuring timely access to essential medical supplies for Veterans, with the contract structured to reimburse vendors per filled prescription at government contract prices, plus handling fees. Interested vendors must submit a capabilities statement to the primary contact, Phillip Reuwer, at Phillip.Reuwer@va.gov by January 11, 2026, with any questions directed to the same contact before January 8, 2026.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    6505--Nicotine Lozenges MINI (VA-26-00020754)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Nicotine Mini Lozenges, specifically under solicitation number 36E79726R0007. This contract aims to ensure an uninterrupted supply of nicotine lozenges for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), with a contract duration of one year and four optional one-year extensions. The estimated annual requirements include 166,791 bottles of 2mg lozenges and 138,276 bottles of 4mg lozenges, which will be distributed through the VA and DOD Pharmaceutical Prime Vendor Programs. Interested offerors should note that the solicitation will be electronically issued around December 18, 2025, with a tentative closing date of January 1, 2026, and can direct inquiries to Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.